Improved preoperative risk stratification in endometrial carcinoma patients: external validation of the ENDORISK Bayesian network model in a large population-based case series.


Journal

Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060

Informations de publication

Date de publication:
Jul 2023
Historique:
received: 24 05 2022
accepted: 18 07 2022
medline: 5 7 2023
pubmed: 9 8 2022
entrez: 8 8 2022
Statut: ppublish

Résumé

Preoperative risk stratification of newly diagnosed endometrial carcinoma (EC) patients has been hindered by only moderate prediction performance for many years. Recently ENDORISK, a Bayesian network model, showed high predictive performance. It was the aim of this study to validate ENDORISK by applying the model to a population-based case series of EC patients. ENDORISK was applied to a retrospective cohort of women surgically treated for EC from 2003 to 2013. Prediction accuracy for LNM as well as 5-year DSS was investigated. The model's overall performance was quantified by the Brier score, discriminative performance by area under the curve (AUC). A complete dataset was evaluable from 247 patients. 78.1% cases were endometrioid histotype. The majority of patients (n = 156;63.2%) had stage IA disease. Overall, positive lymph nodes were found in 20 (8.1%) patients. Using ENDORISK predicted probabilities, most (n = 156;63.2%) patients have been assigned to low or very low risk group with a false-negative rate of 0.6%. AUC for LNM prediction was 0.851 [95% confidence interval (CI) 0.761-0.941] with a Brier score of 0.06. For 5-year DSS the AUC was 0.698 (95% CI 0.595-0.800) as Brier score has been calculated 0.09. We were able to successfully validate ENDORISK for prediction of LNM and 5-year DSS. Next steps will now have to focus on ENDORISK performance in daily clinical practice. In addition, incorporating TCGA-derived molecular subtypes will be of key importance for future extended use. This study may support further promoting of data-based decision-making tools for personalized treatment of EC.

Identifiants

pubmed: 35939115
doi: 10.1007/s00432-022-04218-4
pii: 10.1007/s00432-022-04218-4
pmc: PMC10314833
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3361-3369

Informations de copyright

© 2022. The Author(s).

Références

Cancer. 2017 Mar 1;123(5):802-813
pubmed: 28061006
Lancet. 2016 Mar 12;387(10023):1094-1108
pubmed: 26354523
Updates Surg. 2016 Jun;68(2):149-54
pubmed: 26826083
J Clin Pathol. 2010 May;63(5):410-5
pubmed: 20418232
PLoS Med. 2020 May 15;17(5):e1003111
pubmed: 32413043
J Clin Oncol. 2020 Oct 10;38(29):3388-3397
pubmed: 32749941
Nature. 2013 May 2;497(7447):67-73
pubmed: 23636398
Cochrane Database Syst Rev. 2017 Oct 02;10:CD007585
pubmed: 28968482
Am J Obstet Gynecol. 2017 May;216(5):459-476.e10
pubmed: 27871836
Histopathology. 2020 Jan;76(1):52-63
pubmed: 31846532
Gynecol Oncol. 1983 Feb;15(1):10-7
pubmed: 6822361
Lancet. 2009 Jan 10;373(9658):125-36
pubmed: 19070889
Artif Intell Med. 2004 Mar;30(3):201-14
pubmed: 15081072
CA Cancer J Clin. 2019 Jul;69(4):258-279
pubmed: 31074865
Am J Surg Pathol. 2013 Jun;37(6):874-81
pubmed: 23629444
Ann Oncol. 2018 May 1;29(5):1180-1188
pubmed: 29432521
J Pathol. 2021 Apr;253(4):355-365
pubmed: 33368243
Recent Results Cancer Res. 2016;208:107-136
pubmed: 27909905
Int J Gynecol Cancer. 2021 Jan;31(1):12-39
pubmed: 33397713
Am Soc Clin Oncol Educ Book. 2017;37:435-442
pubmed: 28561715
Mod Pathol. 2013 Dec;26(12):1594-604
pubmed: 23807777
J Cancer Res Clin Oncol. 2019 Jan;145(1):213-221
pubmed: 30460411

Auteurs

Marcel Grube (M)

Department of Women's Health, University Hospital Tuebingen, Calwerstraße 7, 72076, Tuebingen, Germany.

Casper Reijnen (C)

Department of Radiation Oncology, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525 GA, Nijmegen, The Netherlands.

Peter J F Lucas (PJF)

Department of Data Science, University of Twente, Drienerlolaan 5, 7522 NB, Enschede, The Netherlands.

Frieder Kommoss (F)

Institute of Pathology, Im Medizin Campus Bodensee, Röntgenstraße 2, 88048, Friedrichshafen, Germany.

Felix K F Kommoss (FKF)

Institute of Pathology, University Hospital Heidelberg, Im Neuenheimer Feld 672, 69120, Heidelberg, Germany.

Sara Y Brucker (SY)

Department of Women's Health, University Hospital Tuebingen, Calwerstraße 7, 72076, Tuebingen, Germany.

Christina B Walter (CB)

Department of Women's Health, University Hospital Tuebingen, Calwerstraße 7, 72076, Tuebingen, Germany.

Ernst Oberlechner (E)

Department of Women's Health, University Hospital Tuebingen, Calwerstraße 7, 72076, Tuebingen, Germany.

Bernhard Krämer (B)

Department of Women's Health, University Hospital Tuebingen, Calwerstraße 7, 72076, Tuebingen, Germany.

Jürgen Andress (J)

Department of Women's Health, University Hospital Tuebingen, Calwerstraße 7, 72076, Tuebingen, Germany.

Felix Neis (F)

Department of Women's Health, University Hospital Tuebingen, Calwerstraße 7, 72076, Tuebingen, Germany.

Annette Staebler (A)

Department of Pathology and Neuropathology, University Hospital Tuebingen, Liebermeisterstraße 8, 72076, Tuebingen, Germany.

Johanna M A Pijnenborg (JMA)

Department of Obstetrics and Gynaecology, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525 GA, Nijmegen, The Netherlands.

Stefan Kommoss (S)

Department of Women's Health, University Hospital Tuebingen, Calwerstraße 7, 72076, Tuebingen, Germany. Stefan.kommoss@med.uni-tuebingen.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH